Contralateral RRM (CRRM) significantly decreases contralateral BC incidence in both BRCA1/2 pV carriers [6] and reduces overall and BC-specific mortality rates for BRCA1 pV carriers [7]. This evidence concerns the gene BRCA1 and breast cancer.